Baculovirus Expression System Market Size, Share & Trends Analysis Report By Product Type (Baculovirus, Expression Vector, Reagents, Others), By Application (Therapeutics, Vaccines, Protein Purification, Others), By End User (Biopharmaceutical Companies, Research Institutes, Others), By Region, And By Segment Forecasts, 2024-2031

Baculovirus Expression System Market Size is valued at USD 374.79 Mn in 2023 and is predicted to reach USD 660.97 Mn by the year 2031 at a 7.43% CAGR during the forecast period for 2024-2031. 

The baculovirus vector system induces recombinant protein expression in insect cell cultures. It is one of the most adaptable and robust methods for the eukaryotic expression of recombinant proteins. This technique allows for the efficient manufacture of proteins with the appropriate post-translational modifications, making it ideal for use in research of protein function. Safety, quick vector synthesis, the flexibility to use serum-free medium, and efficient protein folding and post-translational modifications are just a few of the many benefits of this technology. Furthermore, the market for biosimilars has grown as the patents on several successful biologics have expired. The biosimilar industry is increasingly turning to baculovirus expression to speed up and reduce the cost of making biosimilar versions of antibodies and proteins. As a result, the baculovirus expression system market is anticipated to benefit from expanding the biologics and biosimilar industries.

However, market expansion is anticipated to be hampered by issues that include the high cost of research and development, the scarcity of supporting infrastructure, the high price of treatment, and the prevalence of market consolidation. Low-cost substitutes, stringent regulatory approvals, the high cost of protein therapy, and a lack of suitable infrastructure in low- and middle-income countries are all expected to slow market expansion over the next few years. The effects of COVID-19 on the market have been adverse. The suspension of elective surgical procedures hampered the potential for the need to expand. In addition, the market was hampered during this pandemic era by restrictions enacted in response to the movement. However, with the forthcoming easings, a recovery is anticipated in the market.

Competitive Landscape

Some Major Key Players In The Baculovirus Expression System Market:

• Thermo Fisher Scientific
• Merck KGaA
• Takara Bio
• Agilent Technologies
• Oxford Expression Technologies
• Promega Corporation
• Qiagen N.V.
• Bio-Rad Laboratories
• New England Biolabs
• Genscript Biotech Corporation
• Syngene International Limited
• Sartorius AG
• Aragen Bioscience
• Vivopure
• Creative Biogene
• Absolute Antibody
• Rockland Immunochemicals
• Protein Technologies Inc.
• Proteogenix
• Virovek
• Others

Market Segmentation:

The baculovirus expression system market is segmented based on product type, application, and end-use industry. According to product type, the market comprises baculovirus, expression vector, reagents, and others. By application, the market is segmented into therapeutics, Vaccines, Protein Purification, and Others. By end-use industry, the market is segmented into biopharmaceutical companies, research institutes, and others.

Based On The Product Type, The Expression Vectors Baculovirus Expression System Market Segment Is Accounted As A Major Contributor To The Baculovirus Expression System Market. 

The expression vectors segment is likely to hold a significant global market share in 2024 in baculovirus expression system market. Expression vectors have been used to transfer genes into plants and animals, resulting in transgenic species used in agriculture. Rice plants have been modified to produce beta-carotene, a precursor to vitamin A, using expression vectors.

Biopharmaceutical Segment To Witness Growth At A Rapid Rate.

The biopharmaceutical industry leads because many medicine manufacturers have developed efficient manufacturing procedures that help keep their goods affordable. Any group working to expand people's access to low-cost medical care may benefit, especially in countries like the US, Germany, the UK, China, and India.

In The Region, The North American Baculovirus Expression System Market Holds A Significant Revenue Share.

The North American baculovirus expression system market is expected to record the maximum market share in revenue in the near future. It can be attributed to the high concentration of top pharmaceutical firms, the massive funding of research and development, and the swift uptake of cutting-edge technologies. In addition, Asia Pacific is estimated to grow rapidly in the global baculovirus expression system market because global biopharma enterprises are increasingly outsourcing bioproduction in light of expanding demand for protein therapies, increasing investments in R&D infrastructure, and rising outsourcing rates.

Recent Developments:

• In March 2022, ProteoGenix declared the introduction of the XtenCHOTM Transient Expression System. The novel proprietary expression host based on mammalian cells obtained up to ten times greater yields with reduced manual labour in comparison to established alternatives; this was due to the optimized metabolism and enhanced stability of the plasmid.   With the new CHO host, recombinant protein synthesis was intended to be simplified, and early-phase drug screening accelerated.

Baculovirus Expression System Market Report Scope